Advertisement

Long-term follow-up in the treatment of peritoneal carcinomatosis

      Abstract

      Background

      The objective of this study was to report a long-term survival analysis of a phase II protocol of cytoreductive surgery (CS) and heated intraperitoneal chemotherapy (HIPEC) in the treatment of peritoneal carcinomatosis (PCs).

      Methods

      Between 2000 and 2008, 101 consecutive patients were treated with CS, HIPEC and early postoperative intraperitoneal chemotherapy using a standardized protocol. Disease recurrence and mortality data were collected prospectively. Primary outcomes were median, 3-year, and 5-year disease-free survival (DFS) and overall survival (OS).

      Results

      The median age was 49 years (range, 18–77 years), and the majority (82%) had complete CS with no gross residual cancer. Tumor types included appendiceal (n = 58), colorectal (n = 31), and other (n = 12). Median follow-up was 28 months (range, 0–119 months), with minimum of 24 months among survivors. For appendiceal tumors, median DFS was 34 months (range, 0–119 months) and OS has not yet been defined. Three-year and 5-year DFS was 48% and 42%, respectively, and 3-year and 5-year OS was 76% and 62%, respectively. For colorectal carcinomatosis, median disease-free and OS was 9 months (range, 0–87 months) and 27 months (range, 0–87 months), respectively. Three-year and 5-year DFS was 34% and 26%, respectively, and 3-year and 5-year OS was 38% and 34%, respectively.

      Conclusions

      Long-term survival with regional treatment of PC from appendiceal or colorectal primary tumors with CS and HIPEC is achievable.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to The American Journal of Surgery
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Glehen O.
        • Osinsky D.
        • Beaujard A.C.
        • et al.
        Natural history of peritoneal carcinomatosis from nongynecologic malignancies.
        Surg Oncol Clin N Am. 2003; 12: 729-739
        • Sugarbaker P.H.
        • Cunliffe W.J.
        • Belliveau J.
        • et al.
        Rationale for integrating early postoperative intraperitoneal chemotherapy into the surgical treatment of gastrointestinal cancer.
        Semin Oncol. 1989; 16: 83-97
        • Miner T.J.
        • Shia J.
        • Jaques D.P.
        • et al.
        Long-term survival following treatment of pseudomyxoma peritonei: an analysis of surgical therapy.
        Ann Surg. 2005; 241: 300-308
        • Yan T.D.
        • Black D.
        • Savady R.
        • et al.
        A systematic review on the efficacy of cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei.
        Ann Surg Oncol. 2007; 14: 484-492
        • Ronnett B.M.
        • Zahn C.M.
        • Kurman R.J.
        • et al.
        Disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis: a clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis, and relationship to “pseudomyxoma peritonei.”.
        Am J Sug Pathol. 1995; 19: 1390-1408
        • Smeenk R.M.
        • Verwaal V.J.
        • Antonini N.
        • et al.
        Survival analysis of pseudomyxoma peritonei patients treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
        Ann Surg. 2007; 245: 104-109
        • Canadian Cancer Society
        Canadian cancer statistics 2010.
        Canadian Cancer Society, Toronto2010
        • Minsky B.D.
        • Mies C.
        • Rich T.A.
        • et al.
        Potentially curative surgery of colon cancer: patterns of failure and survival.
        J Clin Oncol. 1988; 6: 106-118
        • Chu D.Z.
        • Lang N.P.
        • Thompson P.
        • et al.
        Peritoneal carcinomatosis in non-gynecologic malignancy.
        Cancer. 1989; 63: 364-367
        • Sadeghi B.
        • Arvieux C.
        • Glehen O.
        • et al.
        Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study.
        Cancer. 2000; 88: 358-363
        • Jayne D.G.
        • Fook S.
        • Loi C.
        • et al.
        Peritoneal carcinomatosis from colorectal cancer.
        Br J Surg. 2002; 89: 1545-1550
        • de Gramont A.
        • Figer A.
        • Seymour M.
        • et al.
        Leucovorin and fluorouracil with and without oxaliplatin as first-line treatment in advanced colorectal cancer.
        J Clin Oncol. 2000; 18: 2938-2947
        • Bloemendaal A.L.
        • Verwaal V.J.
        • van Ruth S.
        • et al.
        Conventional surgery and systemic chemotherapy for peritoneal carcinomatosis of colorectal origin: a prospective study.
        Eur J Surg Oncol. 2005; 31: 1145-1151
        • Verwaal V.J.
        • Bruin S.
        • Boot H.
        • et al.
        8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer.
        Ann Surg Oncol. 2008; 15: 2426-2432
        • Glehen O.
        • Kwiatkowski F.
        • Sugarbaker P.H.
        • et al.
        Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study.
        J Clin Oncol. 2004; 22: 3284-3292
        • Elias D.
        • Gilly F.
        • Boutite F.
        • et al.
        Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study.
        J Clin Oncol. 2010; 28: 1808
        • Lanuke K.
        • Mack L.A.
        • Temple W.J.
        Phase II study of regional treatment for peritoneal carcinomatosis.
        Am J Surg. 2009; 197: 614-618
        • Sugarbaker P.H.
        Peritonectomy procedures.
        Cancer Treat Res. 1996; 82: 235-253
        • Gonzalez-Moreno S.
        • Sugarbaker P.H.
        Right hemicolectomy does not confer a survival advantage in patients with mucinous carcinoma of the appendix and peritoneal seeding.
        Br J Surg. 2004; 91: 304-311
        • Verwaal V.J.
        • van Ruth S.
        • Witkamp A.
        • et al.
        Long-term survival of peritoneal carcinomatosis of colorectal origin.
        Ann Surg Oncol. 2005; 12: 65-71
        • Maggiori L.
        • Elias D.
        Curative treatment of colorectal peritoneal carcinomatosis: current status and future trends.
        Eur J Surg Oncol. 2009; 36: 599-603
        • Francis W.P.
        • Mack L.A.
        • Temple W.J.
        • et al.
        A prospective comparison of cytoreductive surgery plus heated intraperitoneal chemotherapy and early postoperative chemotherapy vs. heated intraperitoneal chemotherapy alone in the treatment of peritoneal carcinomatosis.
        Ann Surg Oncol. 2010; 17: S8

      Linked Article

      • Erratum
        The American Journal of SurgeryVol. 201Issue 6
        • Preview
          Please be advised that the May 2011 issue (Volume 201, Number 5) of The American Journal of Surgery originally mailed with Discussions omitted from the North Pacific Surgical Association papers. The Publisher regrets this oversight. To rectify the situation, the May 2011 issue was reprinted (Volume 201, Number 5A) to include the full Discussions for the following articles:
        • Full-Text
        • PDF